First Co-morbidity of Lophomonas blattarum and COVID-19 Infections: Confirmed Using Molecular Approach.
Acta Parasitol
; 67(1): 535-538, 2022 Mar.
Article
em En
| MEDLINE
| ID: mdl-34677797
ABSTRACT
INTRODUCTION:
Lophomoniasis is caused by Lophomonas spp., a new emerging protozoan, which commonly affects the human lower respiratory tract. The Lophomonas parasite mostly lives commensally in the hindgut of cockroaches. CASE PRESENTATION We present the case of a 33-year-old woman, 30 weeks pregnant, who had severe COVID-19. She was intubated upon admission and began the routine COVID-19 treatment. To rule out possible super infection dual with COVID-19, microscopic examination of the patient's mini-bronchoalveolar lavage (mini-BAL) specimen, revealed L. blattarum, which was identified by the SSU rRNA-PCR and sequencing approaches (accession number MZ093069). According to that, the patient was treated successfully with metronidazole.CONCLUSION:
To prevent serious complications, lophomoniasis should be listed in co-morbidity cases of COVID-19 infection during the COVID-19 pandemic worldwide. To the best of our knowledge, this is the first co-infection of Lophomonas blattarum and COVID-19 in the world which has been confirmed using a molecular approach.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Parabasalídeos
/
COVID-19
/
Tratamento Farmacológico da COVID-19
Tipo de estudo:
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article